Abstract: A method for producing a carotenoid or apocarotenoid is disclosed. The method comprises the step of expressing in a host cell an expression module comprising an expression vector having a coding region encoding at least one optimised carotenoid or apocarotenoid generating enzyme, the coding region being operably linked to a promoter. A host cell comprising an expression vector having a coding region encoding at least one optimised carotenoid or apocarotenoid generating enzyme, the coding region being operably linked to a promoter is also provided together with a kit.

Abstract: This technology relates to a method of treating breast cancer in a subject and a method of determining whether a breast lesion in a subject is malignant or benign using miRNA panels.

Abstract: A bacterial strain comprising one or more vectors encoding a) one or more enzymes to produce one or more terpene precursors; and b) a fungal terpene synthase (FTPS). The present invention also relates to a method of producing a terpenoid comprising a) culturing the bacterial strain described herein in an expression medium; and b) isolating the terpenoid from said expression medium.

Abstract: The invention relates to the production of one or more terpenoids through microbial engineering, and relates to the manufacture of products comprising terpenoids.

Abstract: Described herein are methods for transfecting mesenchymal stem cells (MSCs) with a nucleic acid construct using a cationic polymer, a first reagent capable of redirecting endocytosed nucleic acids from intracellular acidic compartments, and a second agent capable of stabilizing a microtubular network of the MSCs. The methods are free of virus-based transfection vehicle materials and the transfected MSCs have substantially unchanged multipotent phenotype. In certain embodiments, the transfected MSCs express functional genes comprising suicide gene, such as cytosine deaminase or uracil phosphoribosyltransferase. Also described are methods for the treatment of diseases, such as cancer, using such transfected cells in combination with 5FC, 5FU, GCV, as well as kits and composition relating thereof.

Abstract: The invention provides, inter alia, a nucleic acid (e.g. expression vector) that comprises at least a first coding sequence and a second coding sequence. Each conding sequence is under the control of an inducible promoter of defined strength. Different promoters can have different strengths. Each promoter is responsive to the same inducer. The invention also provides: methods of expressing coding regions, methods of making a product of a multi-enzyme pathway, and methods of optimizing the yield of a product of a multi-enzyme metabolic pathway using the nucleic acids provided by the invention. Also disclosed is a method of non-enzymatic gene cloning useful for practicing the invention.

Abstract: We describe a method of diagnosing a gastric cancer. The method may include detecting the expression level of an miRNA in a sample of or from an individual. The expression level of the miRNA may be detected in an extracellular vesicle (EV) from the sample. The miRNA may be selected from the group consisting of: hsa-miR-484, hsa-miR-186-5p, hsa-miR-142-5p, hsa-miR-320d, hsa-miR-320a, hsa-miR-320b and hsa-miR-17-5p. The method may be such that an altered expression level of the miRNA as compared to the expression level of the miRNA in an EV in or of an individual known not to be suffering from gastric cancer indicates that the individual is suffering, or is likely to be suffering, from gastric cancer.

Abstract: Present application relates to methods for determining whether a subject has heart failure or is at risk of having heart failure, specifically that of heart failure with reduced left ventricular ejection fraction (HFREF) and a heart failure with preserved left ventricular ejection fraction (HFPEF), comprising determining the level of selected miRNA(s) observed in a sample obtained from the subject and wherein an altered level of the miRNA(s) compared to control indicates that the subject has heart failure or is at risk of developing heart failure. Also encompassed are methods of determining an altered risk of death or disease progression to hospitalization and death based on alteration of selected miRNAs in a sample from the subject and kits thereof.

Abstract: The invention provides, inter alia, a nucleic acid (e.g. expression vector) that comprises at least a first coding sequence and a second coding sequence. Each conding sequence is under the control of an inducible promoter of defined strength. Different promoters can have different strengths. Each promoter is responsive to the same inducer. The invention also provides: methods of expressing coding regions, methods of making a product of a multi-enzyme pathway, and methods of optimizing the yield of a product of a multi-enzyme metabolic pathway using the nucleic acids provided by the invention. Also disclosed is a method of non-enzymatic gene cloning useful for practicing the invention.

Abstract: The invention relates to the production of one or more terpenoids through microbial engineering, and relates to the manufacture of products comprising terpenoids.

Abstract: A bacterial strain comprising one or more vectors encoding a) one or more enzymes to produce one or more terpene precursors; and b) a fungal terpene synthase (FTPS). The present invention also relates to a method of producing a terpenoid comprising a) culturing the bacterial strain described herein in an expression medium; and b) isolating the terpenoid from said expression medium.

Abstract: The invention relates to the production of one or more terpenoids through microbial engineering, and relates to the manufacture of products comprising terpenoids.

Abstract: The invention relates to the production of one or more terpenoids through microbial engineering, and relates to the manufacture of products comprising terpenoids.

Abstract: Disclosed are methods of determining the likelihood of a subject having or developing a gastric cancer. The methods comprise measuring the expression level of at least one miRNA having at least 90% sequence identity with an miRNA as described herein in a non-cellular biofluid sample obtained from the subject, wherein differential expression of miRNA expression in the sample obtained from the subject, as compared to a control, may be indicative of the subject having gastric cancer and wherein the miRNA may be either an miRNA listed as “up-regulated” or an miRNA listed as “down-regulated”. Also disclosed is a method of determining the likelihood of a subject having or developing a stage of a gastric cancer.

Abstract: The invention relates to the production of one or more terpenoids through microbial engineering, and relates to the manufacture of products comprising terpenoids.

Abstract: The invention relates to the production of one or more terpenoids through microbial engineering, and relates to the manufacture of products comprising terpenoids.

Abstract: A method for producing a carotenoid or apocarotenoid is disclosed. The method comprises the step of expressing in a host cell an expression module comprising an expression vector having a coding region encoding at least one optimised carotenoid or apocarotenoid generating enzyme, the coding region being operably linked to a promoter. A host cell comprising an expression vector having a coding region encoding at least one optimised carotenoid or apocarotenoid generating enzyme, the coding region being operably linked to a promoter is also provided together with a kit.

Abstract: The invention provides, inter alia, a nucleic acid (e.g. expression vector) that comprises at least a first coding sequence and a second coding sequence. Each conding sequence is under the control of an inducible promoter of defined strength. Different promoters can have different strengths. Each promoter is responsive to the same inducer. The invention also provides: methods of expressing coding regions, methods of making a product of a multi-enzyme pathway, and methods of optimizing the yield of a product of a multi-enzyme metabolic pathway using the nucleic acids provided by the invention. Also disclosed is a method of non-enzymatic gene cloning useful for practicing the invention.

Abstract: The invention relates to recombinant expression of a taxadiene synthase enzyme and a geranylgeranyl diphosphate synthase (GGPPS) enzyme in cells and the production of terpenoids.

Abstract: The invention relates to the production of one or more terpenoids through microbial engineering, and relates to the manufacture of products comprising terpenoids.